Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ImmuPharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Lupus Erythematosus, Systemic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01135459 |
C33457/2047 | P2 |
Completed |
Lupus Erythematosus, Systemic |
2012-01-31 |
2022-12-17 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
2010-018383-16 |
Celestial 47 | P2 |
Completed |
Lupus Erythematosus, Systemic |
2012-01-31 |
2022-03-13 |
Treatments |
|
2007-004892-21 |
2007-004892-21 | P2 |
Completed |
Unknown |
2009-07-21 |
2025-07-09 |
Treatments |
|
NCT03427151 |
IP-006 | P3 |
Completed |
Lupus Erythematosus, Systemic |
2019-02-05 |
26% |
2019-04-12 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
2017-004060-35 |
2017-004060-35 | P3 |
Completed |
Lupus Erythematosus, Systemic |
2019-02-05 |
2022-03-13 |
Treatments |
|
2015-003341-25 |
A study to evaluate the effectiveness and safety of the study drug for patients with SLE. | P3 |
Completed |
Lupus Erythematosus, Systemic |
2018-01-24 |
2025-07-09 |
Treatments |
|
NCT02504645 |
LUPUZOR | P3 |
Completed |
Lupus Erythematosus, Systemic |
2018-01-01 |
19% |
2019-04-12 |
Patient Enrollment|Treatments |
NCT01240694 |
C33457/3075 | P3 |
Terminated |
Lupus Erythematosus, Systemic |
2012-06-14 |
2022-12-31 |
||
2010-019293-32 |
Celestial 75 | P3 |
Terminated |
Lupus Erythematosus, Systemic |
2012-06-14 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/31/2023 |
PubMed |
Immunological and translational key challenges in systemic lupus erythematosus: A symposium update. |
|
02/09/2023 |
News Article |
ImmuPharma expects new Lupozor study to begin in H2 2023 |
|
06/01/2022 |
PubMed |
P140 Peptide Leads to Clearance of Autoreactive Lymphocytes and Normalizes Immune Response in Lupus-Prone Mice. |
|
10/20/2020 |
PubMed |
In Vivo Remodeling of Altered Autophagy-Lysosomal Pathway by a Phosphopeptide in Lupus. |
|
10/08/2020 |
News Article |
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Review, H2 2020 - ResearchAndMarkets.com |
|
03/11/2020 |
News Article |
2020 Chronic Inflammatory Demyelinating Polyneuropathy - Pipeline Review - ResearchAndMarkets.com |
|
11/28/2019 |
News Article |
Global Systemic Lupus Erythematosus (SLE) Market Insights, Epidemiology, and Market Forecasts 2017-2028 - ResearchAndMarkets.com |